[CAS NO. 132-69-4] Benzydaminehydrochloride
PRODUCTS SPECIFICATIONS [132-69-4]
DESCRIPTION [132-69-4]
Overview
| MDL | MFCD00078957 |
|---|---|
| Molecular Weight | 345.87 |
| Molecular Formula | C19H24ClN3O |
| SMILES | CN(C)CCCOC1=NN(CC2=CC=CC=C2)C3=C1C=CC=C3.[H]Cl |
Summary
Benzydamine hydrochloride is a locally-acting nonsteroidal anti-inflammatory drug with local anaesthetic and analgesic properties; selectively binds to prostaglandin synthetase and has notable in vitro antibacterial activity.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02713893 | Aziende Chimiche Riunite Angelini Francesco S.p.A|Cross Research S.A. |
Healthy
|
September 2015 | Phase 1 |
| NCT01637883 | Prince of Songkla University |
For Intervention
|
January 2011 | Phase 3 |
| NCT04941976 | Aziende Chimiche Riunite Angelini Francesco S.p.A|Zak-Pharma Dienstleistung Ges.m.b.H. |
Acute Sore Throat
|
August 13, 2020 | Phase 4 |
| NCT00051441 | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.|Angelini |
Stomatitis|Radiation Effects
|
Phase 3 | |
| NCT03574246 | Ankara University |
Sore Throat|Nausea and Vomiting, Postoperative
|
January 10, 2018 | Phase 4 |
| NCT04373421 | Yuzuncu Y?l University |
Impacted Third Molar Tooth
|
August 15, 2018 | Phase 4 |
| NCT04167592 | Indonesia University |
ERCP
|
August 1, 2018 | Not Applicable |
| NCT05323058 | Cairo University |
Stomatitis
|
July 2022 | Phase 2 |
| NCT05343429 | Rehman Medical Institute - RMI |
Sore Throat
|
April 1, 2022 | Phase 4 |
| NCT02720783 | Aziende Chimiche Riunite Angelini Francesco S.p.A|Cross Research S.A. |
Healthy Women
|
March 4, 2016 | Phase 1 |
| NCT03074968 | Seoul National University Hospital |
Intubation Complication
|
March 8, 2017 | Phase 4 |
| NCT03706781 | Aziende Chimiche Riunite Angelini Francesco S.p.A|Cross Research S.A. |
Healthy
|
November 14, 2017 | Phase 1 |
| NCT05338398 | E2Bio Life Sciences, LLC|Hematology Center after Prof. R. Yeolyan |
Oral Mucositis
|
April 15, 2022 | Phase 1|Phase 2 |
| NCT05055726 | Aziende Chimiche Riunite Angelini Francesco S.p.A|PPD |
Radiation-Induced Mucositis|Head and Neck Cancer
|
December 6, 2021 | Phase 4 |
| NCT03745599 | Near East University, Turkey |
Pain|Quality of Life
|
November 1, 2017 | Phase 4 |
| NCT00814359 | Juravinski Cancer Centre Foundation |
Head and Neck Cancer|Mucositis
|
May 2009 | Phase 3 |
| NCT04303312 | Ghada zaki|Cairo University |
Mucositis Oral
|
December 2021 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
H 2 O : ≥ 41 mg/mL ( 118.54 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.8913 mL | 14.4563 mL | 28.9126 mL |
| 5 mM | 0.5783 mL | 2.8913 mL | 5.7825 mL |
| 10 mM | 0.2891 mL | 1.4456 mL | 2.8913 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (289.13 mM); Clear solution; Need ultrasonic
References
- [1] Anand JS, et al. Recreational abuse with benzydamine hydrochloride (tantum rosa). Clin Toxicol (Phila). 2007;45(2):198-9.
- [2] Opaleye ES, et al. Recreational use of benzydamine as a hallucinogen among street youth in Brazil. Rev Bras Psiquiatr. 2009 Sep;31(3):208-13.
- [3] Mota DM, et al. Use abusive of benzydamine in Brazil: an overview in pharmacovigilance. Cien Saude Colet. 2010 May;15(3):717-24.
- [4] Fanaki NH, et al. Antimicrobial activity of benzydamine, a non-steroid anti-inflammatory agent. J Chemother. 1992 Dec;4(6):347-52.
Synonyms